Related Experiment Video
Updated: May 20, 2026

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
Published on: July 18, 2025
Accelerated renal disease is associated with the development of metabolic syndrome in a glucolipotoxic mouse model
Cristina Martínez-García1, Adriana Izquierdo, Vidya Velagapudi
1Universidad Rey Juan Carlos, Dpto. de Bioquímica, Fisiología y Genética Molecular, Avda. de Atenas s/n. 28922, Alcorcón, Madrid, Spain.
Abstract:
Individuals with metabolic syndrome are at high risk of developing chronic kidney disease (CKD) through unclear pathogenic mechanisms. Obesity and diabetes are known to induce glucolipotoxic effects in metabolically relevant organs. However, the pathogenic role of glucolipotoxicity in the aetiology of diabetic nephropathy is debated. We generated a murine model, the POKO mouse, obtained by crossing the peroxisome proliferator-activated receptor gamma 2 (PPARγ2) knockout (KO) mouse into a genetically obese ob/ob background. We have previously shown that the POKO mice showed: hyperphagia, insulin resistance, hyperglycaemia and dyslipidaemia as early as 4 weeks of age, and developed a complete loss of normal β-cell function by 16 weeks of age. Metabolic phenotyping of the POKO model has led to investigation of the structural and functional changes in the kidney and changes in blood pressure in these mice. Here we demonstrate that the POKO mouse is a model of renal disease that is accelerated by high levels of glucose and lipid accumulation. Similar to ob/ob mice, at 4 weeks of age these animals exhibited an increased urinary albumin:creatinine ratio and significantly increased blood pressure, but in contrast showed a significant increase in the renal hypertrophy index and an associated increase in p27(Kip1) expression compared with their obese littermates. Moreover, at 4 weeks of age POKO mice showed insulin resistance, an alteration of lipid metabolism and glomeruli damage associated with increased transforming growth factor beta (TGFβ) and parathyroid hormone-related protein (PTHrP) expression. At this age, levels of proinflammatory molecules, such as monocyte chemoattractant protein-1 (MCP-1), and fibrotic factors were also increased at the glomerular level compared with levels in ob/ob mice. At 12 weeks of age, renal damage was fully established. These data suggest an accelerated lesion through glucolipotoxic effects in the renal pathogenesis in POKO mice.
Insights
Metabolic syndrome accelerates chronic kidney disease (CKD) in POKO mice. Glucolipotoxicity exacerbates renal damage, inflammation, and fibrosis, highlighting its role in diabetic nephropathy pathogenesis.
Area of Science:
- Nephrology
- Metabolic Diseases
- Genetics
Background:
- Metabolic syndrome increases chronic kidney disease (CKD) risk via unclear mechanisms.
- Glucolipotoxicity from obesity and diabetes is implicated in diabetic nephropathy.
- The POKO mouse model combines PPARγ2 knockout with genetic obesity.
Purpose of the Study:
- To investigate renal structural and functional changes in the POKO mouse model.
- To determine the role of glucolipotoxicity in accelerated kidney disease pathogenesis.
- To analyze blood pressure and molecular changes in POKO mice.
Main Methods:
- Generation of the POKO mouse model (PPARγ2 KO x ob/ob).
- Metabolic phenotyping, including assessment of hyperphagia, insulin resistance, and dyslipidemia.
- Analysis of kidney structure, function (albumin:creatinine ratio), blood pressure, and molecular markers (p27Kip1, TGFβ, PTHrP, MCP-1).
Main Results:
- POKO mice exhibit accelerated renal disease, characterized by increased renal hypertrophy and p27Kip1 expression.
- Glucolipotoxicity in POKO mice leads to glomeruli damage, altered lipid metabolism, and elevated TGFβ, PTHrP, and MCP-1.
- Renal damage is fully established by 12 weeks, suggesting glucolipotoxic effects drive pathogenesis.
Conclusions:
- The POKO mouse is a valuable model for studying accelerated diabetic nephropathy.
- Glucolipotoxicity significantly contributes to the pathogenesis of renal disease in this model.
- Targeting glucolipotoxic pathways may offer therapeutic strategies for CKD in metabolic syndrome.
Related Concept Videos
Diabetic Nephropathy
Type II Diabetes II: Pathophysiology

